Solid Biosciences Inc (SLDB)
8.94
-0.36
(-3.87%)
USD |
NASDAQ |
May 17, 16:00
8.94
0.00 (0.00%)
After-Hours: 20:00
Solid Biosciences Enterprise Value: 137.43M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 137.43M |
| May 16, 2024 | 150.86M |
| May 15, 2024 | 165.83M |
| May 14, 2024 | 176.19M |
| May 13, 2024 | 168.13M |
| May 10, 2024 | 192.70M |
| May 09, 2024 | 185.41M |
| May 08, 2024 | 182.01M |
| May 07, 2024 | 188.44M |
| May 06, 2024 | 172.54M |
| May 03, 2024 | 176.33M |
| May 02, 2024 | 181.25M |
| May 01, 2024 | 155.13M |
| April 30, 2024 | 129.76M |
| April 29, 2024 | 126.73M |
| April 26, 2024 | 133.92M |
| April 25, 2024 | 117.26M |
| April 24, 2024 | 125.97M |
| April 23, 2024 | 138.84M |
| April 22, 2024 | 136.19M |
| April 19, 2024 | 123.32M |
| April 18, 2024 | 144.52M |
| April 17, 2024 | 172.16M |
| April 16, 2024 | 165.73M |
| April 15, 2024 | 172.54M |
| Date | Value |
|---|---|
| April 12, 2024 | 186.27M |
| April 11, 2024 | 197.24M |
| April 10, 2024 | 203.67M |
| April 09, 2024 | 231.29M |
| April 08, 2024 | 244.53M |
| April 05, 2024 | 253.99M |
| April 04, 2024 | 262.32M |
| April 03, 2024 | 267.61M |
| April 02, 2024 | 251.72M |
| April 01, 2024 | 264.59M |
| March 28, 2024 | 379.28M |
| March 27, 2024 | 414.40M |
| March 26, 2024 | 388.72M |
| March 25, 2024 | 389.10M |
| March 22, 2024 | 395.52M |
| March 21, 2024 | 352.85M |
| March 20, 2024 | 377.39M |
| March 19, 2024 | 433.27M |
| March 18, 2024 | 380.79M |
| March 15, 2024 | 370.22M |
| March 14, 2024 | 340.01M |
| March 13, 2024 | 338.13M |
| March 12, 2024 | 306.79M |
| March 11, 2024 | 307.17M |
| March 08, 2024 | 296.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-142.48M
Minimum
Mar 21 2023
757.86M
Maximum
Mar 02 2021
70.47M
Average
53.61M
Median
Sep 28 2020
Enterprise Value Benchmarks
| Sarepta Therapeutics Inc | 12.27B |
| PTC Therapeutics Inc | 1.938B |
| Capricor Therapeutics Inc | 157.31M |
| Catalyst Pharmaceuticals Inc | 1.637B |
| Pfizer Inc | 219.35B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.30M |
| Total Expenses (Quarterly) | 26.86M |
| EPS Diluted (Quarterly) | -0.64 |
| Earnings Yield | -44.02% |
| Normalized Earnings Yield | -126.88 |